<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333200</url>
  </required_header>
  <id_info>
    <org_study_id>PRO11050036</org_study_id>
    <nct_id>NCT03333200</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of Neurodegenerative Disorders</brief_title>
  <official_title>Longitudinal Study of Neurodegenerative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the course of rare genetic disorders that affect
      the brain. This data is being analyzed to gain a better understanding of the progression of
      the rare neurodegenerative disorders and the effects of interventions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients would be evaluated by a multidisciplinary team at specific time points every 3
      months the first year, every 6 months the second year and once a year thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2012</start_date>
  <completion_date type="Anticipated">January 2035</completion_date>
  <primary_completion_date type="Anticipated">January 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive development</measure>
    <time_frame>15 years</time_frame>
    <description>Repeated standardized age equivalent scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Language development</measure>
    <time_frame>15 years</time_frame>
    <description>Repeated standardized age equivalent scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gross Motor development .</measure>
    <time_frame>15 years</time_frame>
    <description>Repeated standardized age equivalent scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fine Motor development</measure>
    <time_frame>15 years</time_frame>
    <description>Repeated standardized age equivalent scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adaptive living skills</measure>
    <time_frame>15 years</time_frame>
    <description>Repeated standardized age equivalent scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory biomarkers</measure>
    <time_frame>15 years</time_frame>
    <description>Blood, CSF and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodegeneration of the brain as measured by MRI diffusion tensor imaging from birth to 5 years of age</measure>
    <time_frame>5 years</time_frame>
    <description>Specialized technique to use DTI data to measure brain degeneration over time</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>MLD</condition>
  <condition>Krabbe Disease</condition>
  <condition>ALD</condition>
  <condition>MPS I</condition>
  <condition>MPS II</condition>
  <condition>MPS III</condition>
  <condition>Vanishing White Matter Disease</condition>
  <condition>GM3 Gangliosidosis</condition>
  <condition>PKAN</condition>
  <condition>Tay-Sachs Disease</condition>
  <condition>NP Deficiency</condition>
  <condition>Osteopetrosis</condition>
  <condition>Alpha-Mannosidosis</condition>
  <condition>Sandhoff Disease</condition>
  <condition>Niemann-Pick Diseases</condition>
  <condition>MPS IV</condition>
  <condition>Gaucher Disease</condition>
  <condition>GAN</condition>
  <condition>GM1 Gangliosidoses</condition>
  <condition>Morquio Disease</condition>
  <condition>S-Adenosylhomocysteine Hydrolase Deficiency</condition>
  <condition>Batten Disease</condition>
  <condition>Pelizaeus-Merzbacher Disease</condition>
  <condition>Leukodystrophy</condition>
  <condition>Lysosomal Storage Diseases</condition>
  <condition>Purine Nucleoside Phosphorylase Deficiency</condition>
  <condition>Multiple Sulfatase Deficiency Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Palliative Care</intervention_name>
    <description>Collecting information about the natural progression of these diseases</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoetic Stem Cell Transplantation</intervention_name>
    <description>Following patients who have received HSCT as part of their clinical care.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      NDRD Biorepository includes: blood plasma and serum, CSF, brain and other tissues
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Persons with genetic neurodegenerative diseases.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with a genetic neurodegenerative disorder

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary Brannaman, MS</last_name>
    <phone>412-692-6350</phone>
    <email>Mary.Brannaman@chp.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Escolar, MD, MS</last_name>
    <phone>412-692-6350</phone>
    <email>maria.escolar@chp.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Program for the Study of Neurodevelopment in Rare Disorders, Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Brannaman, MS</last_name>
      <phone>412-692-6350</phone>
      <email>Mary.Brannaman@chp.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Escolar, MD, MS</last_name>
      <email>maria.escolar@chp.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Maria L Escolar, MD,MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele D. Poe, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Maria Escolar</investigator_full_name>
    <investigator_title>Director, Program for the Study of Neurodevelopment in Rare Disorders Children's Hospital of Pittsburgh of UPMC</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Rare</keyword>
  <keyword>Neurodegenerative</keyword>
  <keyword>Genetic</keyword>
  <keyword>Neurodevelopment</keyword>
  <keyword>Brain</keyword>
  <keyword>MRI</keyword>
  <keyword>Biorepository</keyword>
  <keyword>NDRD</keyword>
  <keyword>Longitudinal</keyword>
  <keyword>Cognitive</keyword>
  <keyword>Motor</keyword>
  <keyword>Language</keyword>
  <keyword>Adaptive behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
    <mesh_term>Mannosidase Deficiency Diseases</mesh_term>
    <mesh_term>alpha-Mannosidosis</mesh_term>
    <mesh_term>Gangliosidoses</mesh_term>
    <mesh_term>Osteopetrosis</mesh_term>
    <mesh_term>Tay-Sachs Disease</mesh_term>
    <mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Leukodystrophy, Globoid Cell</mesh_term>
    <mesh_term>Sandhoff Disease</mesh_term>
    <mesh_term>Leukoencephalopathies</mesh_term>
    <mesh_term>Gangliosidosis, GM1</mesh_term>
    <mesh_term>Pelizaeus-Merzbacher Disease</mesh_term>
    <mesh_term>Mucopolysaccharidosis IV</mesh_term>
    <mesh_term>Osteochondrodysplasias</mesh_term>
    <mesh_term>Purine-Pyrimidine Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Multiple Sulfatase Deficiency Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The IPD will be shared after review and only under a DTA, CDA through our office of research.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

